Ending scarcity for some of the most promising cancer therapeutics
Marathon is producing isotopes to power targeted radiotherapies, building the critical supply chains needed to scale access.
Isotopes enable targeted radiotherapies
In targeted radiotherapy, isotopes are delivered directly to cancer cells, delivering a localized dose of irradiation, while minimizing harm to surrounding tissue. The success and availability of these treatments depends on supply of those isotopes.
A single compact fusion facility could end the shortage permanently
Supply of critical radioisotopes relies on cold war-era stockpiles, leading to shortages, delays and paused patient enrollment. And that's just at the level of clinical trials for thousands of patients.
To make these treatment options widely available, we'll need to scale to millions of doses per year. At kilowatts of power, near term fusion reactors can already produce critically needed isotopes. With just a few megawatts of irradiation power in upcoming facilities, we can put a stop to shortages forever.
Novel production pathways open new therapeutic possibilities
Targeted radiotherapy has been constrained by isotope availability. Some of the most promising preclinical work never makes it to human trials, not for lack of efficacy, but for lack of supply.
Marathon is working on the discovery of novel production pathways to enable supply of the world's rarest isotopes, creating new possibilities and treatment options.